Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple systems. Cardiovascular complications account for up to 30%-40% of the death causes of patients with SLE, and dyslipidemia is one of the core factors driving the increase of cardiovascular risk. Different from dyslipidemia in the general population, dyslipidemia in SLE patients is both “inflammation-driven” and “treatment-induced”, which makes lipid monitoring an integral part of the overall management of SLE, not only to guide the precise adjustment of lipid-lowering drugs and immunotherapy regimens, but also to predict cardiovascular events and disease activity in advance. It will escort the long-term prognosis of patients.
1. “Dual drive” of dyslipidemia in SLE patients: the additive effect of inflammation and treatment
The incidence of dyslipidemia in SLE patients is significantly higher than that in the general population, and about 60%-80% of patients have different degrees of dyslipidemia. The mechanisms can be divided into two categories:
1.1 “Endogenous destruction” of autoinflammation
In the active stage of SLE, a large number of inflammatory factors (such as TNF-α and IL-6) can interfere with lipid metabolism. On the one hand, they inhibit the clearance of low-density lipoprotein cholesterol (LDL-C) by the liver, leading to the accumulation of “bad cholesterol”. On the other hand, it promotes the liver to synthesize more triglyceride (TG) and reduces the “vascular scavenger” function of high-density lipoprotein cholesterol (HDL-C), forming an abnormal spectrum of “high LDL-C, high TG, low HDL-C”. This inflammation-induced dyslipidemia is closely related to SLE disease activity, and the higher the SLEDAI score (disease activity index), the more severe the dyslipidemia. lipid profile meter
1.2 “Exogenous interference” of therapeutic drugs
Long-term use of glucocorticoids and some immunosuppressants is another important trigger of dyslipidemia in SLE patients:
Glucocorticoids can directly promote the synthesis of LDL-C and TG in the liver, and reduce the utilization of lipids in peripheral tissues. After high-dose glucocorticoid treatment, LDL-C can increase by 30%-50%;
Immunosuppressants, such as cyclosporine A and tacrolimus, can affect lipoprotein lipase activity and lead to increased TG level. However, methotrexate may decrease the level of HDL-C.
This dual drive of “inflammation + treatment” makes dyslipidemia in SLE patients more complicated and harmful, and also highlights the necessity of blood lipid monitoring.
2. Blood lipid monitoring to guide clinical medication: precise adjustment, balance efficacy and safety
Blood lipid monitoring is not a simple “index observation”, but the core basis for clinical medication adjustment, mainly reflected in three levels:
2.1 Initiation and dose optimization of lipid-lowering drugs
According to the guidelines for the Diagnosis and Treatment of Systemic Lupus erythematosus (2020 Edition), the lipid management goals for patients with SLE need to be more stringent:
LDL-C should be less than 2.6mmol/L in patients without cardiovascular risk factors.
LDL-C should be less than 1.8mmol/L in patients with hypertension, diabetes or previous cardiovascular events.
Lipid monitoring results directly determine lipid-lowering regimens:
Statins (such as atorvastatin and rosuvastatin) are preferred if LDL-C is mainly elevated, and LDL-C level is monitored to adjust the dose, with the goal of reducing LDL-C by more than 50% compared with baseline.
Fibrates (such as fenofibrate) should be initiated if TG is significantly elevated (≥5.6mmol/L), and liver function and creatine kinase should be monitored to avoid the risk of muscle injury when combined with statins.
For patients with reduced HDL-C, niacin can be considered on the basis of lifestyle intervention, but the potential effect of niacin on SLE inflammation should be vigilant.
2.2 Optimization and adjustment of immunotherapy regimens
Dyslipidemia can reflect the “double-edged sword” effect of immunotherapy and guide the clinical balance between efficacy and safety:
If the patient has a sharp increase in LDL-C after steroid therapy, the dose of steroid can be gradually reduced if the condition permits, or calcineurin inhibitor (such as tacrolimus) can be used to replace part of the hormone, and statins can be added at the same time.
If TG continues to increase after the use of cyclosporine A, mycophenolate mofetil with less effect on blood lipids can be used, or combined with fibrates to control blood lipids.
For patients with severe dyslipidemia in the active stage of disease, immunosuppressive agents should be used to control inflammation. With the decrease of SLEDAI score, lipid levels tend to improve, and the dose of lipid-lowering drugs can be adjusted appropriately.
2.3 Avoidance of drug interactions
Multiple drugs are often used in patients with SLE. Lipid monitoring can detect lipid fluctuations caused by drug interactions in time:
When statins and calcineurin inhibitors are used together, the risk of myopathy will increase. It is necessary to closely monitor creatine kinase and blood lipid, and reduce the dose of statins if necessary.
Glucocorticoid combined with fibrates may increase blood glucose, so blood glucose and blood lipid should be monitored simultaneously, and the medication plan should be adjusted. lipid analysis
3. Blood lipid monitoring helps risk assessment: early warning to reduce cardiovascular events
Patients with SLE have two to ten times the cardiovascular risk of the general population, and lipid monitoring is a key tool for risk stratification and early warning:
3.1 Stratified assessment of cardiovascular risk
In clinical practice, risk stratification is often combined with blood lipid indicators and SLE-specific factors:
Low-risk population: normal blood lipids, no cardiovascular risk factors (hypertension, diabetes, smoking), SLEDAI score < 4; Moderate-risk population: LDL-C≥2.6mmol/L, or combined with 1-2 cardiovascular risk factors; High-risk group: LDL-C≥3.4mmol/L, or combined with more than 3 risk factors, or previous cardiovascular events. The results of blood lipid monitoring can be used to dynamically adjust the risk stratification. For example, patients with low LDL-C > 3.4mmol/L for two consecutive times should be upgraded to moderate risk and strengthened intervention.
3.2 Indirect reflection of disease activity
Lipid parameters are closely related to inflammatory activity in SLE:
When SLE is active, serum amyloid A (SAA) is increased, which leads to the decrease of HDL-C level, and the increase of LDL-C and TG.
If the blood lipid indexes continue to be abnormal after treatment, it indicates that the inflammation has not been effectively controlled, and the immunotherapy regimen needs to be reevaluated.
This “lipid-inflammation” association makes blood lipid monitoring an “indirect vane” of SLE disease activity.
3.3 Early warning of complications
Long-term dyslipidemia can accelerate atherosclerosis. Blood lipid monitoring combined with carotid ultrasound, coronary CT and other examinations can early detect subclinical atherosclerosis:
If LDL-C continues to increase and carotid intima-media thickness (IMT) ≥0.9mm, it indicates the formation of atherosclerosis, and lipid-lowering therapy should be intensified.
If TG≥5.6mmol/L, fibrates should be considered for acute pancreatitis, and fibrates should be started in time.
4. Clinical practice: standardized path of blood lipid monitoring
Blood lipid monitoring in SLE patients should follow the principle of “individualization and dynamic” :
Frequency of surveillance:
Blood lipids were monitored every 1 to 3 months during active disease or after lipid-lowering therapy.
When the condition was stable and blood lipids reached the target, the patients were monitored every 6 months.
Monitoring indicators:
Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) were routinely monitored.
Blood glucose, liver function and creatine kinase were monitored simultaneously when diabetes mellitus was complicated or statins were used.
Multidisciplinary collaboration:
Rheumatology and immunology department, cardiovascular department and endocrinology department were jointly managed, and treatment plan was made according to the results of blood lipid monitoring, taking into account both SLE control and blood lipid management. 5 in 1 lipid test meter
Blood lipid monitoring, the “invisible grasp” of the whole management of SLE
In the treatment of SLE, blood lipid monitoring is often ignored by the thinking of “emphasizing immunity and ignoring metabolism”, but it is a key node connecting disease control, drug adjustment and risk early warning. Through standardized blood lipid monitoring, clinicians can not only accurately adjust immunization and lipid-lowering regimens, balance efficacy and safety, but also identify cardiovascular risk in advance and reduce the incidence of complications. For SLE patients, blood lipid monitoring is not an “additional examination”, but a “necessary guarantee” for long-term quality of life. Paying attention to blood lipid management can make SLE treatment more comprehensive and accurate.
Post time: Mar-18-2026